A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer

Cancer Discovery

Volumn 6, Issue 11, 2016, Pages 1267-1275

  Vijai, Joseph ^a   Topka, Sabine ^a   Villano, Danylo ^a   Ravichandran, Vignesh ^a   Maxwell, Kara N ^b   Maria, Ann ^a   Thomas, Tinu ^a   Gaddam, Pragna ^a   Lincoln, Anne ^a   Kazzaz, Sarah ^a   Wenz, Brandon ^b   Carmi, Shai ^c   Schrader, Kasmintan A ^d   Hart, Steven N ^e   Lipkin, Steve M ^f   Neuhausen, Susan L ^g   Walsh, Michael F ^a   Zhang, Liying ^a   Lejbkowicz, Flavio ^h   Rennert, Hedy ^h   Stadler, Zsofia K ^a,f   Robson, Mark ^a,f   Weitzel, Jeffrey N ^g   Domchek, Susan ^b   Daly, Mark J ^i,j   Couch, Fergus J ^e   Nathanson, Katherine L ^b   Norton, Larry ^a   Rennert, Gad ^h   Offit, Kenneth ^a,f   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e MAYO CLINIC   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h CLALIT HEALTH SERVICES   (Israel)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER RISK; CELL REACTIVATION ASSAY; CELL VIABILITY ASSAY; CLINICAL ARTICLE; COMPLEMENTATION ASSAY; CONTROLLED STUDY; CRISPR CAS SYSTEM; DIAGNOSTIC PROCEDURE; DNA DAMAGE; DNA REPAIR; ERCC3 GENE; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; GENETIC TRANSFECTION; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; NEXT GENERATION SEQUENCING; PHENOTYPE; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT MUTATION; SEQUENCE ANALYSIS; ULTRAVIOLET C RADIATION; WESTERN BLOTTING; AGED; BREAST NEOPLASMS; GENETICS; JEW; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR;

DNA BINDING PROTEIN; DNA HELICASE; XPBC-ERCC-3 PROTEIN;

ADULT; AGED; BREAST NEOPLASMS; CRISPR-CAS SYSTEMS; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; JEWS; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 84995422380     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0487     Document Type: Article

References (37)

1. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014; 343: 1466-70.
2. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015; 372: 2243-57.
3. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373-80.
4. Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell 2004; 6: 539-45.
5. Brosh RM Jr. DNA helicases involved in DNA repair and their roles in cancer. Nat Rev Cancer 2013; 13: 542-58.
6. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 2013; 9: e1003709.
7. Vermeulen W, Scott RJ, Rodgers S, Muller HJ, Cole J, Arlett CF, et al. Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3. Am J Hum Genet 1994; 54: 191-200.
8. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MA, Taetle R. Structure-Activity-Relationships of Illudins-Analogs with Improved Therapeutic Index. J Org Chem 1992; 57: 6876-83.
9. Marti TM, Hefner E, Feeney L, Natale V, Cleaver JE. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc Natl Acad Sci USA 2006; 103: 9891-6.
10. Carmi S, Hui KY, Kochav E, Liu X, Xue J, Grady F, et al. Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nat Commun 2014; 5: 4835.
11. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JH, et al. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science 1993; 260: 58-63.
12. Oh K-S, Khan SG, Jaspers NGJ, Raams A, Ueda T, Lehmann A, et al. Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome. Hum Mut 2006; 27: 1092-103.
13. Singh A, Compe E, Le May N, Egly JM. TFIIH subunit alterations causing xeroderma pigmentosum and trichothiodystrophy specifi-cally disturb several steps during transcription. Am J Hum Genet 2015; 96: 194-207.
14. Seemanova E. An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mut Res 1990; 238: 321-4.
15. Digweed M, Reis A, Sperling K. Nijmegen breakage syndrome: consequences of defective DNA double strand break repair. BioEssays 1999; 21: 649-56.
16. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003; 114: 359-70.
17. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 2003; 114: 371-83.
18. Goss KH, Risinger MA, Kordich JJ, Sanz MM, Straughen JE, Slovek LE, et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 2002; 297: 2051-3.
19. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6: 45-59.
20. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 2013; 4: 2578.
21. Andressoo JO, Weeda G, de Wit J, Mitchell JR, Beems RB, van Steeg H, et al. An Xpb mouse model for combined xeroderma pigmentosum and cockayne syndrome reveals progeroid features upon further attenuation of DNA repair. Mol Cell Biol 2009; 29: 1276-90.
22. Diderich K, Alanazi M, Hoeijmakers JH. Premature aging and cancer in nucleotide excision repair-disorders. DNA Repair (Amst) 2011; 10: 772-80.
23. Itoh T, Cado D, Kamide R, Linn S. DDB2 gene disruption leads to skin tumors and resistance to apoptosis after exposure to ultraviolet light but not a chemical carcinogen. Proc Natl Acad Sci USA 2004; 101: 2052-7.
24. Cheo DL, Meira LB, Burns DK, Reis AM, Issac T, Friedberg E C. Ultraviolet B radiation-induced skin cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer predisposition and pathology of tumors. Cancer Res 2000; 60: 1580-4.
25. Wijnhoven SW, Kool HJ, Mullenders LH, van Zeeland AA, Friedberg EC, van der Horst GT, et al. Age-dependent spontaneous mutagenesis in Xpc mice defective in nucleotide excision repair. Oncogene 2000; 19: 5034-7.
26. Andressoo JO, Mitchell JR, de Wit J, Hoogstraten D, Volker M, Toussaint W, et al. An Xpd mouse model for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predisposition and segmental progeria. Cancer Cell 2006; 10: 121-32.
27. Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005; 14: 555-63.
28. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, et al. The APCI1307K allele and breast cancer risk. Nat Genet 1998; 20: 13-4.
29. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2* 1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008; 26: 542-8.
30. Alanee S, Couch F, Offit K. Association of a HOXB13 variant with breast cancer. N Engl J Med 2012; 367: 480-1.
31. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-9.
32. Schnurbein G, Hauke J, Wappenschmidt B, Weber-Lassalle N, Engert S, Hellebrand H, et al. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res 2013; 15: R120.
33. Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer 2016; 15: 359-66.
34. Sonnenblick A, de Azambuja E, Azim HA Jr., Piccart M. An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 2015; 12: 27-41.
35. Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, et al. The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitro. Mol Pharmacol 2015; 87: 996-1005.
36. Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res 2012; 18: 6400-6.
37. Zhang F. Genome Engineering Resources-Zhang Lab @ MIT. N.p., 2013. Web. 01 Apr. 2016.